Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26493117 | 1.00 | HTR1A (0.58) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL9535253 | 1.00 | HTR1A (0.58) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL9286378 | 0.93 | LMNA (0.59) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL26492991 | 0.91 | HTR1A (0.65) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL26108581 | 0.91 | HTR1A (0.65) | HTR1ADRD2HTR2ADRD3DRD1 | |
| Hydrochloric Acid SCHEMBL26108377 | 0.90 | DRD2 (0.63) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL3910170 | 0.86 | LMNA (0.57) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL9260064 | 0.83 | HTR1A (0.60) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL27715352 | 0.81 | KCNH2 (0.74) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL7488440 | 0.81 | HTR1A (0.58) | HTR1ADRD2HTR2ADRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059807-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | HTR1A 2731/4885DRD2 1993/4885HTR2A 1943/4885 |
| US-11059807-B2 | Amine cationic lipids and uses thereof | SGMS2, SLC43A1, SGMS1 | HTR1A 2731/4885DRD2 1993/4885HTR2A 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.